HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Silica nanomaterials induce organ injuries by Ca2+-ROS-initiated disruption of the endothelial barrier and triggering intravascular coagulation.

AbstractBACKGROUND:
The growing use of silica nanoparticles (SiNPs) in many fields raises human toxicity concerns. We studied the toxicity of SiNP-20 (particle diameter 20 nm) and SiNP-100 (100 nm) and the underlying mechanisms with a focus on the endothelium both in vitro and in vivo.
METHODS:
The study was conducted in cultured human umbilical vein endothelial cells (HUVECs) and adult female Balb/c mice using several techniques.
RESULTS:
In vitro, both SiNP-20 and SiNP-100 decreased the viability and damaged the plasma membrane of cultured HUVECs. The nanoparticles also inhibited HUVECs migration and tube formation in a concentration-dependent manner. Both SiNPs induced significant calcium mobilization and generation of reactive oxygen species (ROS), increased the phosphorylation of vascular endothelial (VE)-cadherin at the site of tyrosine 731 residue (pY731-VEC), decreased the expression of VE-cadherin expression, disrupted the junctional VE-cadherin continuity and induced F-actin re-assembly in HUVECs. The injuries were reversed by blocking Ca2+ release activated Ca2+ (CRAC) channels with YM58483 or by eliminating ROS with N-acetyl cysteine (NAC). In vivo, both SiNP-20 and SiNP-100 (i.v.) induced multiple organ injuries of Balb/c mice in a dose (range 7-35 mg/kg), particle size, and exposure time (4-72 h)-dependent manner. Heart injuries included coronary endothelial damage, erythrocyte adhesion to coronary intima and coronary coagulation. Abdominal aorta injury exhibited intimal neoplasm formation. Lung injuries were smaller pulmonary vein coagulation, bronchiolar epithelial edema and lumen oozing and narrowing. Liver injuries included multifocal necrosis and smaller hepatic vein congestion and coagulation. Kidney injuries involved glomerular congestion and swelling. Macrophage infiltration occurred in all of the observed organ tissues after SiNPs exposure. SiNPs also decreased VE-cadherin expression and altered VE-cadherin spatial distribution in multiple organ tissues in vivo. The largest SiNP (SiNP-100) and longest exposure time exerted the greatest toxicity both in vitro and in vivo.
CONCLUSIONS:
SiNPs, administrated in vivo, induced multiple organ injuries, including endothelial damage, intravascular coagulation, and secondary inflammation. The injuries are likely caused by upstream Ca2+-ROS signaling and downstream VE-cadherin phosphorylation and destruction and F-actin remodeling. These changes led to endothelial barrier disruption and triggering of the contact coagulation pathway.
AuthorsDe-Ping Wang, Zhao-Jun Wang, Rong Zhao, Cai-Xia Lin, Qian-Yu Sun, Cai-Ping Yan, Xin Zhou, Ji-Min Cao
JournalParticle and fibre toxicology (Part Fibre Toxicol) Vol. 17 Issue 1 Pg. 12 (03 23 2020) ISSN: 1743-8977 [Electronic] England
PMID32293491 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Reactive Oxygen Species
  • Silicon Dioxide
Topics
  • Animals
  • Aorta (drug effects, metabolism, pathology)
  • Calcium Signaling (drug effects)
  • Cell Movement (drug effects)
  • Cell Survival (drug effects)
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Endothelium, Vascular (drug effects, metabolism, pathology)
  • Erythrocyte Aggregation (drug effects)
  • Heart (drug effects)
  • Human Umbilical Vein Endothelial Cells (drug effects, metabolism, pathology)
  • Humans
  • Mice, Inbred BALB C
  • Nanoparticles (toxicity)
  • Organ Specificity
  • Particle Size
  • Reactive Oxygen Species (metabolism)
  • Silicon Dioxide (toxicity)
  • Surface Properties

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: